메뉴 건너뛰기




Volumn 38, Issue 6 SUPPL., 2010, Pages

Antimicrobial resistance: Consideration as an adverse drug event

Author keywords

Antimicrobial de escalation; Antimicrobial resistance; Dosing; Duration of therapy; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CILASTATIN; CIPROFLOXACIN; DORIPENEM; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; FLUCONAZOLE; GATIFLOXACIN; IMIPENEM; MACROLIDE; MEROPENEM; METICILLIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

EID: 77953073448     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181de0c26     Document Type: Article
Times cited : (15)

References (64)
  • 1
    • 0021337427 scopus 로고
    • Current mechanisms of resistance to antimicrobial agents in microorganisms causing infection in the patient at risk for infection
    • Neu HS: Current mechanisms of resistance to antimicrobial agents in microorganisms causing infection in the patient at risk for infection. Am J Med 1984; 15:11-27
    • (1984) Am J Med , vol.15 , pp. 11-27
    • Neu, H.S.1
  • 2
    • 33750988183 scopus 로고    scopus 로고
    • Antibiotics past, present, and future
    • Khardori N: Antibiotics Past, present, and future. Med Clin North Am 2006; 90: 1049-1076
    • (2006) Med Clin North Am , vol.90 , pp. 1049-1076
    • Khardori, N.1
  • 3
    • 0032765427 scopus 로고    scopus 로고
    • Correlation between consumption of antimicrobials in humans and development of resistance in bacteria
    • Cristino JM: Correlation between consumption of antimicrobials in humans and development of resistance in bacteria. Int J Antimicrob Agents 1999; 12:199-202
    • (1999) Int J Antimicrob Agents , vol.12 , pp. 199-202
    • Cristino, J.M.1
  • 4
    • 34548225858 scopus 로고    scopus 로고
    • Consumer antibacterial soaps: Effective or just risky?
    • Aiello AE, Larson EL, Levy SB: Consumer antibacterial soaps: Effective or just risky? Clin Infect Dis 2007; 45(Suppl 2):S137-S147
    • (2007) Clin Infect Dis , vol.45 , Issue.SUPPL. 2
    • Aiello, A.E.1    Larson, E.L.2    Levy, S.B.3
  • 5
    • 23244442660 scopus 로고    scopus 로고
    • Hospital and community fluoroquinolone use and resistance in Staphylococcus Aureus and escherichia coli in 17 US hospitals
    • MacDougall C, Powell JP, Johnson K, et al: Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005; 41:435-440
    • (2005) Clin Infect Dis , vol.41 , pp. 435-440
    • MacDougall, C.1    Powell, J.P.2    Johnson, K.3
  • 6
    • 38449092874 scopus 로고    scopus 로고
    • Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus Aureus and Pseudomonas Aeruginosa isolates from 47 French hospitals
    • Rogues AM, Dumartin C, Venier AG, et al: Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol 2007; 28:1389-1395
    • (2007) Infect Control Hosp Epidemiol , vol.28 , pp. 1389-1395
    • Rogues, A.M.1    Dumartin, C.2    Venier, A.G.3
  • 7
    • 33644909052 scopus 로고    scopus 로고
    • Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus Aureus infection by encouraging decreased fluoroquinolone use
    • Madaras-Kelly KJ, Remington RE, Lewis PG, et al: Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol 2006; 27:155-169
    • (2006) Infect Control Hosp Epidemiol , vol.27 , pp. 155-169
    • Madaras-Kelly, K.J.1    Remington, R.E.2    Lewis, P.G.3
  • 8
    • 33646912478 scopus 로고    scopus 로고
    • Fluoroquinolone-resistant Pseudomonas Aeruginosa: Assessment of risk factors and clinical impact
    • Gasink LB, Fishman NO, Weiner MG, et al: Fluoroquinolone-resistant Pseudomonas aeruginosa: Assessment of risk factors and clinical impact. Am J Med 2006; 119: 526.e19-e25
    • (2006) Am J Med , vol.119
    • Gasink, L.B.1    Fishman, N.O.2    Weiner, M.G.3
  • 9
    • 0033059706 scopus 로고    scopus 로고
    • Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents
    • Carmeli Y, Troileet N, Eliopoulous GM, et al: Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43:1379-1382
    • (1999) Antimicrob Agents Chemother , vol.43 , pp. 1379-1382
    • Carmeli, Y.1    Troileet, N.2    Eliopoulous, G.M.3
  • 10
    • 0038708419 scopus 로고    scopus 로고
    • The effect of an antimicrobial restriction program on Pseudomonas Aeruginosa resistance to beta-lactams in a large teaching hospital
    • Regal RE, DePestel DD, VandenBussche HL: The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to beta-lactams in a large teaching hospital. Pharmacotherapy 2003; 23: 618-624
    • (2003) Pharmacotherapy , vol.23 , pp. 618-624
    • Regal, R.E.1    DePestel, D.D.2    VandenBussche, H.L.3
  • 11
    • 66149118585 scopus 로고    scopus 로고
    • Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa
    • Pakyz ALA, Oinonen M, Polk RE: Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53:1983-1986
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 1983-1986
    • Pakyz, A.L.A.1    Oinonen, M.2    Polk, R.E.3
  • 12
    • 27744532776 scopus 로고    scopus 로고
    • Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan
    • Hsueh PR, Chen WH, Luh KT: Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents 2005; 26:463-472
    • (2005) Int J Antimicrob Agents , vol.26 , pp. 463-472
    • Hsueh, P.R.1    Chen, W.H.2    Luh, K.T.3
  • 13
    • 33749028483 scopus 로고    scopus 로고
    • Imipenem resistance among Pseudomonas Aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes
    • Lautenbach E, Weiner MG, Nahamkin I, et al: Imipenem resistance among Pseudomonas aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006; 27:893-900
    • (2006) Infect Control Hosp Epidemiol , vol.27 , pp. 893-900
    • Lautenbach, E.1    Weiner, M.G.2    Nahamkin, I.3
  • 14
    • 0346100720 scopus 로고    scopus 로고
    • Risk factors for acquisition of imipenem-resistant Acinetobacter baumanii: A case-control study
    • Lee SO, Kim NJ, Choic SH, et al: Risk factors for acquisition of imipenem-resistant Acinetobacter baumanii: A case-control study. Antimicrob Agents Chemother 2004; 48: 224-228
    • (2004) Antimicrob Agents Chemother , vol.48 , pp. 224-228
    • Lee, S.O.1    Kim, N.J.2    Choic, S.H.3
  • 15
    • 53949085115 scopus 로고    scopus 로고
    • Association between antibiotic usage and subsequent colonization or infection of extensive drugresistant Acinetobacter Baumanii:A matched case-control study in intensive care units
    • Tsai HT, Wang JT, Chen CJ, et al: Association between antibiotic usage and subsequent colonization or infection of extensive drugresistant Acinetobacter baumanii:A matched case-control study in intensive care units. Diagn Microbiol Infect Dis 2008; 62: 298-305
    • (2008) Diagn Microbiol Infect Dis , vol.62 , pp. 298-305
    • Tsai, H.T.1    Wang, J.T.2    Chen, C.J.3
  • 16
    • 0036736403 scopus 로고    scopus 로고
    • Pharmacodynamics of cefepime in patients with gram-negative infections
    • Tam VH, McKinnon PS, Akins RL, et al: Pharmacodynamics of cefepime in patients with gram-negative infections. J Antimicrob Chemother 2002; 50:425-428
    • (2002) J Antimicrob Chemother , vol.50 , pp. 425-428
    • Tam, V.H.1    McKinnon, P.S.2    Akins, R.L.3
  • 17
    • 0030067765 scopus 로고    scopus 로고
    • Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections
    • Benko AS, Cappelletty DM, Kruse JA, et al: Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections. Antimicrob Agents Chemother 1996; 40:691-695
    • (1996) Antimicrob Agents Chemother , vol.40 , pp. 691-695
    • Benko, A.S.1    Cappelletty, D.M.2    Kruse, J.A.3
  • 18
    • 0041778291 scopus 로고    scopus 로고
    • Steadystate plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe pneumonia
    • Boselli E, Breilh D, Duflo F, et al: Steadystate plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe pneumonia. Crit Care Med 2003; 31: 2102-2106
    • (2003) Crit Care Med , vol.31 , pp. 2102-2106
    • Boselli, E.1    Breilh, D.2    Duflo, F.3
  • 19
    • 35848946597 scopus 로고    scopus 로고
    • Optimal dosing of piperacillin-tazobactam for the treatment of pseudomonas aeruginosa infections: Prolonged or continuous infusion?
    • Kim A, Sutherland CA, Kuti JL, et al: Optimal dosing of piperacillin-tazobactam for the treatment of pseudomonas aeruginosa infections: Prolonged or continuous infusion? Pharmacotherapy 2007; 27:1490-1497
    • (2007) Pharmacotherapy , vol.27 , pp. 1490-1497
    • Kim, A.1    Sutherland, C.A.2    Kuti, J.L.3
  • 20
    • 65649084153 scopus 로고    scopus 로고
    • Population pharmacokinetics of high-dose, prolonged infusion cefepime in adult critically ill patients with ventilator-associated pneumonia
    • Nicasio AM, Ariano RE, Zelenitsky SA, et al: Population pharmacokinetics of high-dose, prolonged infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009; 53:1476-1481
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 1476-1481
    • Nicasio, A.M.1    Ariano, R.E.2    Zelenitsky, S.A.3
  • 21
    • 28844443170 scopus 로고    scopus 로고
    • Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of pseudomonas aeruginosa
    • Tam VH, Schilling AN, Neshat S, et al: Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49:4920-4927
    • (2005) Antimicrob Agents Chemother , vol.49 , pp. 4920-4927
    • Tam, V.H.1    Schilling, A.N.2    Neshat, S.3
  • 22
    • 41649099025 scopus 로고    scopus 로고
    • Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilatorassociated pneumonia: A multicenter, randomized study
    • Chastre J, Wunderink R, Prokacimaer P, et al: Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilatorassociated pneumonia: A multicenter, randomized study. Crit Care Med 2008; 36: 1089-1096
    • (2008) Crit Care Med , vol.36 , pp. 1089-1096
    • Chastre, J.1    Wunderink, R.2    Prokacimaer, P.3
  • 23
    • 49949099257 scopus 로고    scopus 로고
    • Antibiotic resistance - What's dosing got to do with it?
    • Roberts JA, Kruger P, Paterson DL, et al: Antibiotic resistance-What's dosing got to do with it? Crit Care Med 2008; 36:2433-2440
    • (2008) Crit Care Med , vol.36 , pp. 2433-2440
    • Roberts, J.A.1    Kruger, P.2    Paterson, D.L.3
  • 24
    • 0027161344 scopus 로고
    • Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
    • Forrest A, Mix DE, Ballow CH, et al: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-1081
    • (1993) Antimicrob Agents Chemother , vol.37 , pp. 1073-1081
    • Forrest, A.1    Mix, D.E.2    Ballow, C.H.3
  • 25
    • 0031663388 scopus 로고    scopus 로고
    • Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis
    • Lipman J, Scribante J, Gous A, et al: Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. Antimicrob Agents Chemother 1998; 42:2235-2239
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 2235-2239
    • Lipman, J.1    Scribante, J.2    Gous, A.3
  • 26
    • 0031940776 scopus 로고    scopus 로고
    • Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
    • Thomas J, Forrest A, Bhavnani J, et al: Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-527
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 521-527
    • Thomas, J.1    Forrest, A.2    Bhavnani, J.3
  • 27
    • 0023119430 scopus 로고
    • Clinical response to aminoglycoside therapy: The importance of peak concentration to minimal inhibitory concentration
    • Moore RD, Lietman PS, Smith CR: Clinical response to aminoglycoside therapy: The importance of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99
    • (1987) J Infect Dis , vol.155 , pp. 93-99
    • Moore, R.D.1    Lietman, P.S.2    Smith, C.R.3
  • 28
    • 0023176033 scopus 로고
    • Comparative study with enoxacin and netilmicin in a pharmcodynamic model to determine the importance of ratio of peak concentration to MIC for bactericidal activity and emergence of resistance
    • Blaser J, Stone BB, Groner MC, et al: Comparative study with enoxacin and netilmicin in a pharmcodynamic model to determine the importance of ratio of peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31:1054-1060
    • (1987) Antimicrob Agents Chemother , vol.31 , pp. 1054-1060
    • Blaser, J.1    Stone, B.B.2    Groner, M.C.3
  • 29
    • 0031829599 scopus 로고    scopus 로고
    • PharmacodynamicAntibiotics alone and in combination
    • Schentag J, Meagher A, Forrest J: Pharmacodynamic interactions of antibiotics alone and in combination. Clin Infect Dis 1998; 27:40-46
    • (1998) Clin Infect Dis , vol.27 , pp. 40-46
    • Schentag, J.1    Meagher, A.2    Forrest, J.3
  • 30
    • 0035577355 scopus 로고    scopus 로고
    • Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates
    • El Amari E, Chamot E, Auckenthaler R, et al: Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001; 33:1859-1864
    • (2001) Clin Infect Dis , vol.33 , pp. 1859-1864
    • El Amari, E.1    Chamot, E.2    Auckenthaler, R.3
  • 31
    • 21844464306 scopus 로고    scopus 로고
    • Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: A meta-analysis of randomized, controlled trials
    • Bliziotis I, Samonis G, Vardakas K, et al: Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41:149-158
    • (2005) Clin Infect Dis , vol.41 , pp. 149-158
    • Bliziotis, I.1    Samonis, G.2    Vardakas, K.3
  • 32
    • 77950189404 scopus 로고    scopus 로고
    • Available at Accessed October 29
    • Centers for Disease Control and Prevention: Campaign to prevent antimicrobial resistance in healthcare settings. Available at: http://www.cdc.gov/drugresistance/healthcare. Accessed October 29, 2009
    • (2009) Centers for Disease Control and Prevention
  • 33
    • 33846153776 scopus 로고    scopus 로고
    • Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship
    • Dellit TH, Owens RC, McGowan JE, et al: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-177
    • (2007) Clin Infect Dis , vol.44 , pp. 159-177
    • Dellit, T.H.1    Owens, R.C.2    McGowan, J.E.3
  • 34
    • 37549020378 scopus 로고    scopus 로고
    • Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008
    • Dellinger RP, Levy MM, Carlet JM, et al: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
    • (2008) Crit Care Med , vol.36 , pp. 296-327
    • Dellinger, R.P.1    Levy, M.M.2    Carlet, J.M.3
  • 35
    • 13644269309 scopus 로고    scopus 로고
    • Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia
    • American Thoracic Society and the Infectious Diseases Society of America
    • American Thoracic Society and the Infectious Diseases Society of America: Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416
    • (2005) Am J Respir Crit Care Med , vol.171 , pp. 388-416
  • 36
    • 66949140382 scopus 로고    scopus 로고
    • Clinical practice guidelines for the diagnosis and management of intravascular catheterrelated infection: 2009 update by the Infectious Diseases Society of America
    • Mermel LA, Allon M, Bouza E, et al: Clinical practice guidelines for the diagnosis and management of intravascular catheterrelated infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1-45
    • (2009) Clin Infect Dis , vol.49 , pp. 1-45
    • Mermel, L.A.1    Allon, M.2    Bouza, E.3
  • 38
    • 34548164363 scopus 로고    scopus 로고
    • De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate
    • Giantsou E, Liratzopoulos N, Efraimidou E, et al: De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 2007; 33:1533-1540
    • (2007) Intensive Care Med , vol.33 , pp. 1533-1540
    • Giantsou, E.1    Liratzopoulos, N.2    Efraimidou, E.3
  • 39
    • 67650576613 scopus 로고    scopus 로고
    • Utility of preliminary bronchoalveolar lavage results in suspected ventilator-associated pneumonia
    • Swanson JM, Wood GC, Croce MA, et al: Utility of preliminary bronchoalveolar lavage results in suspected ventilator-associated pneumonia. J Trauma 2008; 65:1271-1277
    • (2008) J Trauma , vol.65 , pp. 1271-1277
    • Swanson, J.M.1    Wood, G.C.2    Croce, M.A.3
  • 40
    • 27144463065 scopus 로고    scopus 로고
    • Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results
    • Kollef MH, Kollef KE: Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest 2005; 128:2706-2713
    • (2005) Chest , vol.128 , pp. 2706-2713
    • Kollef, M.H.1    Kollef, K.E.2
  • 41
    • 2442589404 scopus 로고    scopus 로고
    • A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia
    • Micek ST, Ward S, Fraser VJ, et al: A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125:1791-1799
    • (2004) Chest , vol.125 , pp. 1791-1799
    • Micek, S.T.1    Ward, S.2    Fraser, V.J.3
  • 42
    • 2942748293 scopus 로고    scopus 로고
    • The appropriate diagnostic threshold for ventilator-associated pneumonia using quantitative cultures
    • Croce MA, Fabian TC, Mueller EW, et al: The appropriate diagnostic threshold for ventilator-associated pneumonia using quantitative cultures. J Trauma 2004; 56:931-936
    • (2004) J Trauma , vol.56 , pp. 931-936
    • Croce, M.A.1    Fabian, T.C.2    Mueller, E.W.3
  • 43
    • 0042821718 scopus 로고    scopus 로고
    • Optimal threshold for diagnosis of ventilator-associated pneumonia using bronchoalveolar lavage
    • Miller PR, Meredith JW, Change MC: Optimal threshold for diagnosis of ventilator-associated pneumonia using bronchoalveolar lavage. J Trauma 2003; 55:263-268
    • (2003) J Trauma , vol.55 , pp. 263-268
    • Miller, P.R.1    Meredith, J.W.2    Change, M.C.3
  • 44
    • 8544252455 scopus 로고    scopus 로고
    • Deescalation therapy in ventilator-associated pneumonia
    • Rello J, Vidaur L, Sandiumenge A, et al: Deescalation therapy in ventilator-associated pneumonia. Crit Care Med 2004; 32: 2183-2190
    • (2004) Crit Care Med , vol.32 , pp. 2183-2190
    • Rello, J.1    Vidaur, L.2    Sandiumenge, A.3
  • 45
    • 33646471520 scopus 로고    scopus 로고
    • Clinical characteristics and treatment patterns among patients with ventilatorassociated pneumonia
    • Kollef MH, Morrow LE, Niederman MS, et al: Clinical characteristics and treatment patterns among patients with ventilatorassociated pneumonia. Chest 2006; 129: 1210-1218
    • (2006) Chest , vol.129 , pp. 1210-1218
    • Kollef, M.H.1    Morrow, L.E.2    Niederman, M.S.3
  • 46
    • 0034979537 scopus 로고    scopus 로고
    • Experience with a clinical guideline for the treatment of ventilator-associated pneumonia
    • Ibrahim EH, Ward S, Sherman G, et al: Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-1115
    • (2001) Crit Care Med , vol.29 , pp. 1109-1115
    • Ibrahim, E.H.1    Ward, S.2    Sherman, G.3
  • 47
    • 0345283255 scopus 로고    scopus 로고
    • Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial
    • Chastre J, Wolff M, Fagon JY, et al: Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003; 290: 2588-2598
    • (2003) JAMA , vol.290 , pp. 2588-2598
    • Chastre, J.1    Wolff, M.2    Fagon, J.Y.3
  • 48
    • 38949118024 scopus 로고    scopus 로고
    • Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator-associated pneumonia
    • Mueller EW, Croce MA, Boucher BA, et al: Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator-associated pneumonia. J Trauma 2007; 63:1329-1337
    • (2007) J Trauma , vol.63 , pp. 1329-1337
    • Mueller, E.W.1    Croce, M.A.2    Boucher, B.A.3
  • 49
    • 0037074188 scopus 로고    scopus 로고
    • Treatment and outcome of Staphylococcus Aureus bacteremia: A prospective study of 278 cases
    • Jensen AG, Wachmann CH, Espersen F, et al: Treatment and outcome of Staphylococcus aureus bacteremia: A prospective study of 278 cases. Arch Intern Med 2002; 162:25-32
    • (2002) Arch Intern Med , vol.162 , pp. 25-32
    • Jensen, A.G.1    Wachmann, C.H.2    Espersen, F.3
  • 50
    • 62449183879 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of vancomycin in adult patients: A consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists
    • Rybak MJ, Lomaestro BM, Rotscahfer JC, et al: Therapeutic drug monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82-98
    • (2009) Am J Health Syst Pharm , vol.66 , pp. 82-98
    • Rybak, M.J.1    Lomaestro, B.M.2    Rotscahfer, J.C.3
  • 51
    • 23044433603 scopus 로고    scopus 로고
    • Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy
    • Bond CA, Raehl CL: Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am J HealthSyst Pharm 2005; 62:1596-1605
    • (2005) Am J HealthSyst Pharm , vol.62 , pp. 1596-1605
    • Bond, C.A.1    Raehl, C.L.2
  • 54
    • 23844497745 scopus 로고    scopus 로고
    • Strategies to prevent antimicrobial resistance in the intensive care unit
    • Kollef MH, Micek ST: Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 2005; 33:1845-1853
    • (2005) Crit Care Med , vol.33 , pp. 1845-1853
    • Kollef, M.H.1    Micek, S.T.2
  • 55
    • 0038468770 scopus 로고    scopus 로고
    • Routine cycling of antimicrobial agents as an infection-control measure
    • Fridkin SK: Routine cycling of antimicrobial agents as an infection-control measure. Clin Infect Dis 2003; 36:1438-1444
    • (2003) Clin Infect Dis , vol.36 , pp. 1438-1444
    • Fridkin, S.K.1
  • 56
    • 45249099998 scopus 로고    scopus 로고
    • Increase in adult clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005
    • Zilberberg MD, Shorr AF, Kollef MH: Increase in adult clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14:929-931
    • (2008) Emerg Infect Dis , vol.14 , pp. 929-931
    • Zilberberg, M.D.1    Shorr, A.F.2    Kollef, M.H.3
  • 57
    • 58749095113 scopus 로고    scopus 로고
    • Strategies to prevent Clostridium Difficile infections in acute care hospitals
    • Dubberke ER, Gerding DN, Classen D, et al: Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29:S81-S92
    • (2008) Infect Control Hosp Epidemiol , vol.29
    • Dubberke, E.R.1    Gerding, D.N.2    Classen, D.3
  • 58
    • 35748932057 scopus 로고    scopus 로고
    • Safety concerns with fluoroquinolones
    • Mehlhorn AJ, Brown DA: Safety concerns with fluoroquinolones. Ann Pharmacother 2007; 14:1859-1866
    • (2007) Ann Pharmacother , vol.14 , pp. 1859-1866
    • Mehlhorn, A.J.1    Brown, D.A.2
  • 59
    • 55249105923 scopus 로고    scopus 로고
    • Clostridium difficileMore difficult than ever
    • Kelly CP, LaMont JT: Clostridium difficileMore difficult than ever. N Engl J Med 2008; 359:1932-1940
    • (2008) N Engl J Med , vol.359 , pp. 1932-1940
    • Kelly, C.P.1    LaMont, J.T.2
  • 60
    • 0032526223 scopus 로고    scopus 로고
    • Hospital-wide restriction of clindamycin: Effect on the incidence of Clostridium difficileassociated diarrhea and cost
    • Climo MW, Israel DS, Wong ES, et al: Hospital-wide restriction of clindamycin: Effect on the incidence of Clostridium difficileassociated diarrhea and cost. Ann Intern Med 1998; 128:989-995
    • (1998) Ann Intern Med , vol.128 , pp. 989-995
    • Climo, M.W.1    Israel, D.S.2    Wong, E.S.3
  • 61
    • 61849140052 scopus 로고    scopus 로고
    • Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital
    • Kallen AJ, Thompson A, Ristaino P, et al: Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol 2009; 30: 264-272
    • (2009) Infect Control Hosp Epidemiol , vol.30 , pp. 264-272
    • Kallen, A.J.1    Thompson, A.2    Ristaino, P.3
  • 62
    • 33847273700 scopus 로고    scopus 로고
    • Pharmacodynamic target attainment of six betalactams and two fluoroquinolones against Pseudomonas aeruginosaAcinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States Intensive Care Unites in 2004
    • DeRyke CA, Kuti JL, Nicolau DP: Pharmacodynamic target attainment of six betalactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States Intensive Care Unites in 2004. Pharmacotherapy 2007; 27:333-342
    • (2007) Pharmacotherapy , vol.27 , pp. 333-342
    • DeRyke, C.A.1    Kuti, J.L.2    Nicolau, D.P.3
  • 63
    • 60549098868 scopus 로고    scopus 로고
    • Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America
    • Pappas PG, Kauffman CA, Andes D, et al: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535
    • (2009) Clin Infect Dis , vol.48 , pp. 503-535
    • Pappas, P.G.1    Kauffman, C.A.2    Andes, D.3
  • 64
    • 56049120807 scopus 로고    scopus 로고
    • Treatment-related risk factors for hospital mortality in Candida bloodstream infections
    • Labelle AG, Micek ST, Roubinian N, et al: Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36:2967-2972
    • (2008) Crit Care Med , vol.36 , pp. 2967-2972
    • Labelle, A.G.1    Micek, S.T.2    Roubinian, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.